Mangoceuticals (MGRX) Common Equity (2022 - 2025)
Mangoceuticals' Common Equity history spans 4 years, with the latest figure at $15.2 million for Q4 2025.
- On a quarterly basis, Common Equity rose 8.99% to $15.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.2 million, a 8.99% increase, with the full-year FY2025 number at $15.2 million, up 8.99% from a year prior.
- Common Equity hit $15.2 million in Q4 2025 for Mangoceuticals, down from $15.7 million in the prior quarter.
- Over the last five years, Common Equity for MGRX hit a ceiling of $20.3 million in Q1 2025 and a floor of -$958468.0 in Q1 2024.
- Historically, Common Equity has averaged $9.3 million across 4 years, with a median of $13.8 million in 2024.
- Biggest five-year swings in Common Equity: tumbled 125.1% in 2024 and later soared 2212.82% in 2025.
- Tracing MGRX's Common Equity over 4 years: stood at $614029.0 in 2022, then grew by 26.18% to $774754.0 in 2023, then soared by 1700.07% to $13.9 million in 2024, then grew by 8.99% to $15.2 million in 2025.
- Business Quant data shows Common Equity for MGRX at $15.2 million in Q4 2025, $15.7 million in Q3 2025, and $19.2 million in Q2 2025.